Impact of thoracic radiotherapy on first‐line treatment outcomes in ES ‐ SCLC patients
Cancer Medicine · 2024
DOI: 10.1002/cam4.70175 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Xiaoli Mu und 13 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Small Cell Lung Carcinoma. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: West China Hospital of Sichuan University 2023 Clinical Research Incubation Project, 2022 Wu Jieping Medical Foundation, Sichuan Provincial Science and Technology Support Program.
Abstract (Originalsprache)
Background
The therapeutic advantage of thoracic radiotherapy (tRT) as an adjunct to first‐line immunotherapy and chemotherapy in patients with extensive‐stage small cell lung cancer (ES‐SCLC) remains unclear. We sought to elucidate this in a retrospective cohort study comparing the effectiveness and safety of tRT in combination with first‐line immunotherapy and chemotherapy.
Methods
Our retrospective study included patients with ES‐SCLC, treated at the West China Hospital between January 2019 and December 2022. They received first‐line immunotherapy and chemotherapy and were categorized into two cohorts based on the administration of tRT. The primary outcomes were overall survival (OS) and progression‐free survival (PFS). Cox regression analysis was utilized to identify potential independent predictors of prognosis and to compare the treatment outcomes across various patient subgroups. Treatment‐related toxicities across both cohorts were compared using the Chi‐squared test.
Results
A total of 99patients were eligible for the study, out of which 55 received tRT. The medianduration of follow‐up was 39 months. Remarkably, patients who received tRTdemonstrated superior OS and PFS in comparison to those who did not ( P < 0.05). Subgroup analysis further confirmed these findings. Multivariate analysisidentified treatment group and liver metastasis as independent prognosticfactors ( P < 0.05). The incidence of grade 3‐4 adverse events showed nostatistically significant difference between the two cohorts.
Conclusions
Thus, weconfirmed that the addition of tRT to the conventional regimen of first‐linechemotherapy and immunotherapy yields better survival outcomes without asignificant increase in toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- Lung cancer center, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Yixin Zhou, Qing Liu, Panwen Tian, Yan Zhang, Jiyan Liu, Yan Li
Förderung
- West China Hospital of Sichuan University 2023 Clinical Research Incubation Project
- 2022 Wu Jieping Medical Foundation
- Sichuan Provincial Science and Technology Support Program
- Clinical and Translational Medicine Research Special Programme, Chinese Academy of Medical Sciences
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Mu, X., Zhou, Y., Liu, Q., Wang, J., Xu, F., Luo, F., Wang, K., Li, L., Tian, P., Li, Y., Liu, J., Zhang, Y., Liu, J., & Li, Y. (2024). Impact of thoracic radiotherapy on first‐line treatment outcomes in ES ‐ SCLC patients. Cancer Medicine. https://doi.org/10.1002/cam4.70175
Vancouver
Mu X, Zhou Y, Liu Q, Wang J, Xu F, Luo F, et al. Impact of thoracic radiotherapy on first‐line treatment outcomes in ES ‐ SCLC patients. Cancer Medicine. 2024. doi:10.1002/cam4.70175
BibTeX
@article{Mu2024,
author = {Mu, Xiaoli and Zhou, Yixin and Liu, Qing and Wang, Jiantao and Xu, Feng and Luo, Feng and Wang, Ke and Li, Lu and Tian, Panwen and Li, Yalun and Liu, Jiewei and Zhang, Yan and Liu, Jiyan and Li, Yan},
title = {Impact of thoracic radiotherapy on first‐line treatment outcomes in ES ‐ SCLC patients},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70175}
}
EUVIMED